Skip to main content

Table 1 Adverse events experienced by patients treated with antiviral schedule regimens

From: Safety of new DAAs for chronic HCV infection in a real life experience: role of a surveillance network based on clinician and hospital pharmacist

  SOF/LDV SOF/DAK SOF/SIM+/− RBV SOF/RBV OMB/PTR/r/DAS +/− RBV
ENROLLED PTS per regimen 20 15 28 4 11
PTS WITH SERIOUS ADRs 4 (20%) 3 (20%) 1 (4%) 1 (25%) 1 (9%)
DISCONTINUATION 3 0 0 0 1
DEATHS 0 0 0 0 0
COMMON ADRs 10 (50%) 6 (40%) 12 (43%) 4 (100%) 5 (45%)
FATIGUE 6 5 11 4 4
HEADACHE 0 0 0 0 0
NAUSEA 0 0 0 0 0
PRURITUS 0 0 4 0 0
INSOMNIA 1 3 0 0 0
DIARRHOEA 0 0 0 0 0
ASTHENIA 7 2 11 4 3
RASH 0 0 4 0 0
IRRITABILITY 0 4 0 0 0
ANAEMIA 6 3 12 3 3
DYSPNOEA 2 0 0 0 1
  1. *Common adverse drug reactions are not to single patients, one patient may experience more than one common adverse drug reaction. Data are expressed as absolute number plus percentage